Market Context: A Structural Inflection
APAC investors are entering 2026 at a moment of profound transition. Capital markets are no longer defined by simple cycles of expansion and contraction, but by structural shifts in where innovation is created, how capital is deployed, and what ultimately drives resilient returns.
Our latest life sciences research highlights that while global vacancy rates across key lab and cGMP markets rose to 23.1% by year‑end 2025, new construction pipelines have fallen to historic lows. This divergence has created a market characterised by near‑term oversupply alongside constrained medium‑term optionality. At the same time, global R&D property investment rebounded sharply, reaching US$13.5 billion in 2025, up 28% year‑on‑year, underscoring renewed investor conviction where long‑term fundamentals remain intact.
Capital Markets: From Allocation to Precision
For much of the past decade, growth in APAC rewarded scale. Today, scale alone is no longer sufficient. Investors are increasingly focused on precision, directing capital toward assets, platforms and markets that offer clearer visibility, defensibility and global relevance.
Across the region, this shift is evident in three consistent patterns:
- Later‑stage bias is becoming more pronounced, as capital prioritises clearer pathways to monetisation and exit.
- Cross‑border strategies are evolving, with APAC innovation increasingly oriented toward global demand rather than purely domestic markets.
- Selectivity within alternatives is replacing broad thematic exposure, particularly in sectors shaped by technology, regulation and demographic change.
These dynamics are reshaping investment decision‑making across private capital, real assets and strategic partnerships.
The Chinese Mainland in the Global Life Sciences Ecosystem
Life Sciences on the Chinese Mainland: City‑Level Differentiation
The report highlights Beijing, Shanghai and Suzhou as representative life sciences hubs within the Chinese mainland. Together, they illustrate how the Chinese mainland’s life sciences sector functions as an integrated system rather than a single‑market opportunity.
Beijing: Discovery, Policy and Early‑Stage Innovation
Beijing continues to serve as the Chinese mainland’s centre of academic research, early‑stage discovery and policy influence. The city benefits from a dense concentration of universities, national research institutes and regulatory bodies, supporting early‑stage innovation and translational research. For investors, Beijing represents exposure to the front end of the innovation pipeline, where intellectual property is created and scientific direction is established.
Shanghai: Commercialisation and Global Connectivity
Shanghai has emerged as the Chinese mainland’s most internationally connected life sciences market. It plays a central role in commercialisation, multinational pharmaceutical activity and capital access, acting as a gateway between domestic innovation and global markets. The city’s mature ecosystem supports late‑stage development, partnerships and cross‑border transactions, making it a focal point for investors seeking platforms with international scalability.
Suzhou: Manufacturing, Scale‑Up and Industrial Life Sciences
Suzhou complements Beijing and Shanghai through its strength in manufacturing, scale‑up and industrial life sciences. The city has established itself as a key base for biomanufacturing, CDMO activity and operational execution. For investors, Suzhou highlights the importance of production capability, efficiency and supply‑chain integration within the Chinese mainland’s life sciences ecosystem.
Technology as a Filter, Not a Theme
Technology, particularly data‑driven and AI‑enabled platforms, features prominently in the report. However, the key message for investors is not technological optimism, but disciplined differentiation.
While technology is improving efficiency, accelerating development timelines and enhancing decision‑making, it does not eliminate risk. Investors achieving consistent outcomes are those pairing technology exposure with proven adoption, clear integration into value chains, and platforms that remain relevant across market cycles. In this context, technology functions increasingly as a filter, rather than a blanket allocation.
Real Assets: Quality, Location and Optionality
Within real assets, particularly in specialised and operationally intensive life sciences sectors, the report points to a renewed emphasis on quality and optionality. Investors are differentiating between assets that can adapt to changing demand and those that cannot.
Rather than waiting for full recovery signals, many investors are positioning ahead of inflection points, accepting near‑term volatility in exchange for medium‑term structural alignment. This approach places a premium on local market insight combined with regional perspective, an area where APAC‑based investors are well positioned.
Implications for APAC Investors
Based on the findings of the report, several implications emerge:
- Prioritise precision over scale, focusing capital on assets and platforms with clear strategic relevance.
- Re‑evaluate Chinese mainland exposure through a global lens, emphasising cross‑border innovation, partnerships and IP‑led expansion.
- Be selective within technology and alternatives, favouring adoption‑driven platforms over thematic exposure.
- Lean into quality in real assets, targeting locations and assets with operational resilience and future adaptability.
- Use APAC as a portfolio diversifier, recognising differentiated funding cycles, policy frameworks and capital dynamics across the region.
From Insight to Action
This article is part of Capital Compass, our APAC investor newsletter. Stay updated with the latest investment insights in your mailbox by subscribing here.
